Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

pulation.

Other Preclinical Programs:

-- Preclinical data presented at the 5th Annual International

Anti-Angiogenesis Conference confirmed that Peregrine's fully human,

selective anti-VEGF antibody R84 was as effective as Avastin(R) in

inhibiting tumor growth in a model of human breast cancer. Selective

anti-VEGF agents may have potential advantages over non-selective

approaches.

Avid Bioservices:

-- Wholly owned manufacturing subsidiary Avid Bioservices signed an

agreement with ARIUS Research to produce clinical supplies of their

lead cancer stem cell anti-CD44 antibody.

-- Avid continued to demonstrate strong revenue performance during the

third quarter of fiscal year 2008.

Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infec
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 W. ... the release of the REVELERIS® Prep purification ... chemists, preparative chromatographers, and other researchers to perform ... a single unit. , With the REVELERIS® Prep ... and preparative chromatography modes with a simple touch ...
(Date:7/30/2014)... 30, 2014  The Chicago Bears are excited to ... Dermatology (Academy) in an effort to raise awareness of ... host free SPOT me™ skin cancer screenings at a ... Field. SPOT me™ is an educational campaign designed ... and risks of skin cancer, and encourages people to ...
(Date:7/30/2014)... Geneva, Switzerland (PRWEB) July 30, 2014 ... proven technologies for biologic drug discovery and mammalian cell ... SURE CHO-Mplus Libraries ™ will be presented at ... conference being held, September 8 – 10, 2014 ... Berkeley, California. , The following abstract will be ...
(Date:7/30/2014)... NewYork (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
Breaking Biology Technology:Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3
... Tiger and Jacky tip shapes,stand out in Terumo,s newest ... Terumo Interventional Systems announces the launch of Optitorque(TM), ... Tiger and,Jacky tip shapes designed and cleared specifically for ... "The Optitorque catheters, specially designed for radial approach, will,help ...
... biofuel market is estimated at 33 billion with a double digit ... biodiesel. Bioethanol is produced and consumed mainly in Brazil and North ... biodiesel production and this fuel represents about ¾ of the European ... ...
... PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation ... "Company") today announced,that the company will attend the 20th ... The 20th Annual Piper Jaffray Health ... to Wednesday, December 3, 2008, at the New York,Palace ...
Cached Biology Technology:Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters 2Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 4
(Date:7/30/2014)... The Jackson Laboratory has received a pledge of $1 ... and name the Laboratory,s new Neurobehavioral Biometry Center. ... Biometry Center will enable the Laboratory to develop a ... with the ultimate goal of accelerating the pace of ... will serve as a premier resource for the Laboratory ...
(Date:7/30/2014)... Soon, protection from HIV infection could be as simple ... sex. , University of Washington bioengineers have discovered ... that protects women from contracting HIV. Their method spins ... in contact with moisture, releasing higher doses of the ... gels or creams. , "This could offer women a ...
(Date:7/30/2014)... , July 30, 2014 ... mitigation and liveness detection solutions for the biometric ... an industry consortium revolutionizing online authentication with standards ... Mark Cornett , "The decision to join FIDO ... biometric authentication pervasive in use. We believe the ...
Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3NexID Biometrics Joins the FIDO Alliance 2
... Mass., May 5 Aware, Inc. (Nasdaq: AWRE ... today reported financial results for its first quarter ended March ... were $4.6 million, a decrease of 22% compared to $5.9 ... its net income and basic and diluted net income per ...
... influenza infection severity have been identified from past outbreaks. ... described in the open access journal BMC Microbiology ... Jonathan Allen and Tom Slezak from Lawrence Livermore National ... acid markers from past pandemic flu strains two weeks ...
... Ind. - Researchers at Purdue University have found a ... in searches for specific genes that shed light on ... Andrew DeWoody, a professor of genetics, and postdoctoral ... step called normalization is no longer necessary with recent ...
Cached Biology News:Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6Random picks better than complicated process in gene identification 2
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
...
IHC Select Anti-p53, prediluted,wild & mutant, a.a. 19-26, clone DO-7 Immunogen: Human p53 Available Date: 37775...
Tube-O-DIALYZER Floats, small....
Biology Products: